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INTRODUCTION
In recent years, adeno-associated virus (AAV) vectors have gained 
an increasing attention as a gene therapy vector for several diseases, 
some of which have made it to clinical trials.1 The first approved 
AAV-based gene therapy in the Western world is alipogene tiparv-
ovec for the treatment of lipoprotein deficiency, which shows that 
this approach can be successfully and safely applied to monogenic 
diseases.2 Additionally, AAV vectors for the treatment of more com-
plex diseases such as heart failure have seen some success in clinical 
trials,3,4 and many advances are made using these vectors as cancer 
therapeutics.5
Glioblastoma (GBM) is the most common and highest-grade mali-
gnant primary brain tumor in adults. Despite aggressive therapies, 
median survival is generally just over one year following diagnosis.6 
This underscores the need for novel treatments to be developed. 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is 
considered as a potent anti-cancer agent, capable of inducing cell 
death in a variety of tumor cells, including GBM.7–10 Direct intracra-
nial injection of different AAV vectors into the primary tumor mass 
have been used for the treatment of GBM (and other brain tumors) 
with some success, however, due to the invasive nature of this type 
of cancer, tumor recurrence is typically observed showing that a 
vector with widespread gene delivery in the brain is required for 
efficient therapy.11–13
AAV9 serotype is very efficient in transducing cells in vivo, and has 
been shown to cross the blood–brain barrier (BBB) upon intravenous 
injection, making it an ideal candidate for whole brain transduction 
and potential gene delivery to brain tumors.14–19 However, AAV9 
shows high tropism towards the liver, which may cause off-target 
toxicity and limit the potential therapeutic effect.18,20,21 In order to 
restrict AAV-mediated expression to the brain/tumor environment, 
a brain cell-specific promoter could be used, such as the neuron-
specific enolase (NSE) promoter, which is predominantly active in 
neurons, thus limiting expression in other cell types/tissues.22,23 The 
aim of the current study is to evaluate systemic injection of AAV9 
vector expressing a therapeutic gene (secreted soluble TRAIL as a 
model) under the control of either a constitutively active promoter 
or neuron-specific promoter for potential therapy of tumors in the 
brain.
RESULTS
AAV9 transgene expression driven by different promoters has a 
similar kinetics profile.
We cloned the Firefly luciferase bioluminescent reporter under the 
control of either a constitutively active CBA promoter or neuron-
specific NSE promoter and packaged them into AAV9 vector gener-
ating AAV9-CBA-Fluc and AAV9-NSE-Fluc (Figure 1a). Athymic nude 
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Adeno-associated virus (AAV) vectors expressing tumoricidal genes injected directly into brain tumors have shown some promise, 
however, invasive tumor cells are relatively unaffected. Systemic injection of AAV9 vectors provides widespread delivery to the 
brain and potentially the tumor/microenvironment. Here we assessed AAV9 for potential glioblastoma therapy using two different 
promoters driving the expression of the secreted anti-cancer agent sTRAIL as a transgene model; the ubiquitously active chicken 
β-actin (CBA) promoter and the neuron-specific enolase (NSE) promoter to restrict expression in brain. Intravenous injection 
of AAV9 vectors encoding a bioluminescent reporter showed similar distribution patterns, although the NSE promoter yielded 
100-fold lower expression in the abdomen (liver), with the brain-to-liver expression ratio remaining the same. The main cell types 
targeted by the CBA promoter were astrocytes, neurons and endothelial cells, while expression by NSE promoter mostly occurred 
in neurons. Intravenous administration of either AAV9-CBA-sTRAIL or AAV9-NSE-sTRAIL vectors to mice bearing intracranial patient-
derived glioblastoma xenografts led to a slower tumor growth and significantly increased survival, with the CBA promoter having 
higher efficacy. To our knowledge, this is the first report showing the potential of systemic injection of AAV9 vector encoding a 
therapeutic gene for the treatment of brain tumors.
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mice (n = 4 per group) were then injected i.v. via the tail vein with 
1.5 × 1012 g.c./kg of each vector and bioluminescence imaging (BLI) 
was performed at three and twelve days post-injection to quantify 
the distribution of transgene expression. Widespread delivery of 
both vectors was observed throughout the animal’s body at both 
time points (Figure 1b). Analysis of the signal from the head and 
the abdomen of mice at the two time points showed that, at twelve 
days post administration, AAV9-NSE-Fluc vector yielded an average 
of 100-fold lower BLI signal in the abdomen (P = 0.0171) as well as 
the brain (P = 0.0193) of mice compared to the AAV9-CBA-Fluc vec-
tor, indicating that the NSE promoter could be used to decrease 
transgene expression and potential cytotoxicity in the liver and 
other tissues (Figure 1b,c). Despite the difference in transgene 
expression, both vectors yielded a similar expression kinetics profile 
without significant differences in absolute brain-to-liver expression 
ratios (Figure 1d). To confirm these results ex vivo, mice were sacri-
ficed 20 days postinjection of either vector, and the brain and liver 
were  harvested, homogenized, and analyzed for Fluc expression 
(normalized to total amount of protein). In line with the expression 
ratio results obtained by BLI (Figure 1d), an average of 10-fold lower 
signal in both liver (P = 0.004) and the brain (n.s.) was observed 
with the NSE promoter compared to the CBA promoter (Figure 1e), 
with no significant differences in the brain-to-liver ratio between 
both vectors (Figure 1f ).
NSE promoter in AAV9 vector transduces mainly neurons in the 
brain upon i.v. injection
The observed decreased overall expression of the AAV9-NSE-Fluc 
vector could be due to several factors, including a lower number of 
cells transduced, expression level per cell, or both. To confirm cell-
type selectivity of the NSE promoter, we generated AAV9 vectors 
expressing GFP under either promoter (AAV9-CBA-GFP and AAV9-
NSE-GFP; Figure 2a). These vectors were injected i.v. into nude mice 
(n = 3 per group) at a dose of 5 × 1013 g.c/kg. Two weeks post-vector 
injection, mice were sacrificed, and the brain and liver were col-
lected, sectioned and stained for GFP expression. In mice injected 
with AAV9-CBA-GFP, expression of GFP was detected in endothe-
lial cells, neurons and astrocytes in the brain (Figure 2b). On the 
other hand, and as expected, the most common cell type with GFP 
expression in the brain of mice injected with AAV9-NSE-GFP were 
neurons (Figure 2c). In these mice, some dim GFP expression was 
also observed in endothelial cells while no GFP expression corre-
lated with astrocytes. Furthermore, GFP staining in AAV9-NSE-GFP 
mice brains coincided mostly with NeuN staining and not with GFAP 
staining (Supplementary Figure S1), demonstrating that indeed neu-
rons were transduced. Liver sections showed GFP staining, although 
it was more widespread and intense in sections from mice injected 
with AAV9-CBA-GFP vector compared to those injected with AAV9-
NSE-GFP vector (Figure 2b,c). We also quantified the number of 
GFP+ cells in three sections and averaged the total  number of GFP+ 
cells per mm2 showing no significant differences in the number of 
GFP+ neurons, however significantly more astrocytes (P < 0.01) and 
liver cells (P < 0.05) expressed GFP in mice injected with AAV9-CBA-
GFP as compared to AAV9-NSE-GFP (Figure 2d).
Intravascular administration of AAV9-sTRAIL vectors inhibits GBM 
growth in a patient-derived orthotopic xenograft mouse model
In order to assess the potential use of AAV9 vector for systemic 
delivery of therapeutics to brain tumors, we used the secreted 
soluble variant of TRAIL as a transgene model and cloned it under 
the control of NSE or CBA promoter (AAV-CBA-sTRAIL or AAV-NSE-
sTRAIL; Figure 3a). Initially, to assess that sTRAIL is secreted in an 
active form using both constructs, we packaged them into an AAV2 
vector and then transduced 293T cells with either vectors or AAV2-
NSE-Fluc as a control. Conditioned medium from these cells were 
collected and used to treat primary GBM neurospheres in triplicate. 
The AAV-NSE-Fluc control medium had no effect on cell viability. 
On the other hand, a significantly lower number of viable cells were 
observed in wells treated with AAV2-CBA-sTRAIL medium, killing 
60% of GBM neurospheres as compared to the control group 
(P = 0.0008) as well as in GBM neurospheres treated with AAV2-NSE-
sTRAIL medium (P = 0.0006; Figure 3b).
We then assessed whether systemic delivery of AAV9-sTRAIL 
could target the brain tumor environment, while evaluating both 
CBA and NSE promoters to drive sTRAIL transgene expression, to 
determine if a restricted promoter also has a similar therapeutic 
effect in vivo. For evaluation of these vectors, we used an invasive 
patient-derived xenograft orthotopic mouse model.11,24 Mice were 
intracranially injected in the left striatum with 2 × 104 of primary 
GBM stem-like cells culture as neurospheres and expressing Firefly 
luciferase (GBM-Fluc). Twenty-eight days post-tumor cells implanta-
tion, mice were pseudo-randomized into treatment groups so that 
each group had a similar average Fluc signal (P > 0.9999; Figure 4 
and Supplementary Figure S2) and each group received i.v. injec-
tion of 2 × 1013 g.c./kg of either AAV9-CBA-GFP (control, n = 5), AAV9-
CBA-sTRAIL (n = 10) or AAV9-NSE-sTRAIL (n = 10). Tumor volume 
was monitored weekly by Fluc bioluminescence imaging. After the 
first week post-vector injection, the Fluc signal in the control group 
had increased significantly, compared to the AAV9-NSE-sTRAIL 
group (P = 0.0419) and compared to the AAV9-CBA-sTRAIL group 
(P = 0.0356), but there was no significant difference between both 
treatment groups (Figure 4a,b). Between 2 and 3 weeks post-vector 
injection, all mice in the control group had reached their maximum 
Fluc tumor signal, after which they were sacrificed due to predeter-
mined humane endpoints. Imaging showed that tumors in both the 
AAV9-NSE-sTRAIL group and AAV9-CBA-sTRAIL group continued to 
slowly grow, with the former group showing slightly more growth. 
However, no significant differences were found at any time point 
in the Fluc signal between AAV9-NSE-sTRAIL and AAV9-CBA-sTRAIL 
groups.
Survival analysis showed that there was an overall significant 
difference between all groups (P < 0.0001). Post-hoc analysis 
showed that the survival of control mice was significantly shorter 
than that of mice treated with AAV9-NSE-sTRAIL (P = 0.0002) and 
those treated with AAV9-CBA-sTRAIL (P < 0.0001). This shows that 
sTRAIL treatment using i.v. administered AAV9 vectors under either 
promoter provided a therapeutic benefit. Although there was a 
trend for  longer survival in mice treated with AAV9-CBA-sTRAIL as 
compared to AAV9-NSE-sTRAIL, there was no significant difference 
between the two vector-treated groups (P = 0.0998), despite the fact 
that Fluc imaging showed a larger tumor size in mice treated with 
AAV9-NSE-sTRAIL, and that these mice subsequently died sooner. 
Median survival for the control group was 38 days, while mice 
treated with AAV9-NSE-sTRAIL or AAV9-CBA-sTRAIL had a median 
survival of 47 and 54.5 days, respectively (Figure 4c). Furthermore, 
a small subset of mice (n = 3) with AAV9-CBA-sTRAIL survived out 
to the predetermined end of the study (135 days; Figure 4c). This 
indicates a trend for longer survival in mice treated with the vector 
using the CBA promoter over the NSE promoter. To our knowledge, 
this is the first report showing systemic injection of an AAV vector to 
treat tumors in the brain.
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Figure 1  Expression profile and quantitation of adeno-associated virus (AAV)9-mediated bioluminescence expression using chicken β-actin (CBA) 
or neuron-specific enolase (NSE) promoters. Plasmids were designed for the production of AAV9-CBA-Fluc or AAV9-NSE-Fluc (a). Female nude mice 
(n = 4 per group) were injected with 1.5 × 1012 g.c./kg of each vector and images were taken from the dorsal side and ventral side at three and twelve 
days after administration. A representative mouse at each time point is shown for AAV9-CBA-Fluc (b, left panel) and AAV9-NSE-Fluc (b, right panel). 
At 3 and 12 days post vector administration, quantification of the average radiance showed that there is a 100-fold higher signal from the head 
and abdomen (c) in mice injected with AAV9-CBA-Fluc compared to AAV9-NSE-Fluc. No differences in head-to-abdomen ROI ratios were found 
(d). Tissue homogenates showed 10-fold higher relative light units (RLU)/mg in the brain and liver of mice injected with AAV9-CBA-Fluc compared 
to AAV9-NSE-Fluc (e), with no significant differences in the brain-to-liver tissue homogenate ratios (f). Note the scale difference between left and 
right axis in c and e (*P < 0.05; **P < 0.005).
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Next, we performed ex vivo histological analysis using H&E stain-
ing and Ki-67 staining for cell proliferation on brains of mice sacri-
ficed at 6 weeks post-tumor inoculation. In addition, as TRAIL might 
induce hepatotoxicity and AAV9 is known to efficiently transduce 
cells in the liver, we also performed H&E staining on liver sections 
to establish whether this therapy caused any histopathological 
changes. Gross histological analysis did not reveal any visible differ-
ences in liver sections across the different groups (Supplementary 
Figure S3). Large tumors were found at the injection site in the brains 
of mice from the control group. In contrast, much fewer tumor cells 
Figure 2 Brain cell specificity and liver expression with AAV9-CBA-GFP or AAV9-NSE-GFP vector. Mice were injected i.v. with 5 × 1013 g.c./kg of AAV9-
CBA-GFP or AAV9-NSE-GFP vector (a), perfused 2 weeks later and brains and livers were harvested and stained for GFP. In the brains of mice injected 
with AAV9-CBA-GFP (b, top panel), astrocytes (1), neurons (2) and endothelial cells (3) clearly expressed GFP, while primarily neurons (2) expressed 
GFP in brains of mice injected with AAV9-NSE-GFP (c, top panel). Both vectors efficiently transduced neurons and expressed GFP. Expression of GFP 
was also detected in the liver, with higher expression in the livers of mice injected with AAV9-CBA-GFP (b, lower panel) than AAV9-NSE-GFP (c, lower 
panel). Scale bar: 50 µm. Quantitation of GFP+ cells was averaged over three sections and the number of GFP+ cells per mm2 was calculated and 
plotted (d) (*P < 0.05; **P < 0.01).
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were visible on H&E stained sections of mice brains in the AAV9-
NSE-sTRAIL or AAV9-CBA-sTRAIL groups (Figure 4d). Ki-67 staining 
often matched H&E staining and was observed around tumor sites 
in all brain sections, indicating actively proliferating cells (Figure 4d).
DISCUSSION
The use of AAV as a preclinical gene therapy delivery vector has 
resulted in significant successes.1 The ability of AAV9 to efficiently 
pass the BBB after intravascular (i.v.) administration makes this sero-
type uniquely suited for gene therapy of the CNS, particularly the 
brain.16,18 GBM is an aggressive form of primary brain cancer that is 
notoriously resistant to therapies. The presence of death signaling 
receptors on the membrane of GBM cells makes their ligand, TRAIL, 
a potential therapy. Unfortunately, the short half-life and its inabil-
ity to cross the blood–brain barrier are a major problem when using 
recombinant TRAIL protein for therapy in the brain.25,26 AAV vectors 
encoding TRAIL have been utilized for the treatment of many forms 
of cancer, although most studies use intratumoral or near-tumor 
administration27–29 rather than systemic administration.30,31 In case of 
the brain, systemic delivery is hampered due to limited BBB penetra-
tion and subsequent poor brain distribution of many AAV vectors and 
TRAIL protein.11,21,25 Here we used i.v.-administered AAV9 vectors for 
delivery of sTRAIL (as a transgene model) to the primary tumor mass 
and infiltrating tumor cells in the brain. Although TRAIL’s proapoptotic 
effects are confined to tumor cells,32–34 high levels of TRAIL or other 
transgene expression in the liver21,35 become a concern leading to 
toxicity.36,37 To overcome potential liver toxicity, we used the neuron-
specific enolase (NSE) promoter, predominantly active in neurons,22 
and compared it to the ubiquitously active chicken beta-actin (CBA) 
promoter. Our data show that the NSE promoter reduced transgene 
expression in the brain and the liver by at least 10-fold compared to 
the CBA promoter, although the brain-to-liver ratio remained the 
same. This is likely due to the fact that in adult mice, AAV9 primarily 
transduces astrocytes.17 By restricting expression to mostly neurons 
in the brain, we likely lowered the overall transgene expression levels 
in the brain. Indeed, we observed that while the CBA promoter leads 
to expression in most cell types in the brain, most notably neurons, 
astrocytes and endothelial cells, the NSE promoter leads to a more 
confined expression in neurons with low expression in endothelial 
cells and much less expression in the liver. Further, the NSE promoter 
may also be weaker on a per neuron basis than the CBA promoter, 
in line with other studies.38,39 In the future, we may be able to main-
tain high expression of transgene in the brain and lower expression 
in the liver by employing miR122 target sites into the 3’UTR of the 
transgene cassette as previously described.40
We have previously shown that intracranially administered 
AAVrh.8-sTRAIL was capable of combating primary GBM tumor mass 
in a nude mouse model, however, single vector injection was not able 
to combat invasive cells, which managed to escape the zone of resis-
tance and form a new tumor elsewhere in the mouse brain leading to 
tumor recurrence.11 In addition to intracranial injections being a labo-
rious procedure, i.v. administration of a therapeutic vector with wide-
spread CNS transduction would be advantageous since it could tar-
get both the primary tumor mass as well as infiltrative tumor cells in 
the brain. Indeed, a single i.v. injection of either AAV9-CBA-sTRAIL or 
AAV9-NSE-sTRAIL vectors lead to a significantly slower tumor growth 
Figure 3 Cells transduced with AAV-CBA-sTRAIL or AAV-NSE-sTRAIL secrete TRAIL in an active form. 293T cells were transduced with either AAV2-
CBA-sTRAIL, AAV2-NSE-sTRAIL (a) or AAV2-NSE-Fluc control vector. Three days later, conditioned medium was transferred to wells containing GBM 
neurospheres, and the next day cell viability was measured (b). GBM cell viability decreased significantly in wells treated with AAV2-CBA-sTRAIL or 
AAV2-NSE-sTRAIL compared to control wells (**P < 0.001).
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and increase in survival rate as compared to mice treated with AAV9-
CBA-GFP control vector. Although there was a general trend in slower 
tumor growth and increase in survival of mice treated with AAV9-
CBA-sTRAIL as compared to AAV9-NSE-sTRAIL vector, there were no 
significant differences between both groups showing the efficacy of 
neuron-specific promoter with lower liver transduction in combating 
aggressive GBM cells. To our knowledge, this is the first report show-
ing that systemic injection of an AAV vector could treat tumors in the 
brain using a brain-specific promoter with lower liver expression.
Massive invasion of the brain is a major problem in controlling 
GBM growth. Unfortunately, this therapy did not sufficiently inhibit 
the spread of GBM cells to other parts of the brain, away from the pri-
mary tumor site and eventually all mice died. Additionally,  resistance 
to therapy (including TRAIL) is a major problem for the treatment of 
GBM.41–43 We initially tried a relatively low dose of AAV9-sTRAIL (2 × 1013 
g.c./kg). A higher dose of AAV9-sTRAIL or multiple rounds of therapy, 
combined with TRAIL-sensitizing agents,44–47 may achieve a greater 
benefit for inhibiting the invasive growth of GBM and prevent intrinsic 
or acquired TRAIL resistance. TRAIL did not appear to have affected the 
liver, as there was no indication of liver toxicity in both AAV-sTRAIL-
treated groups as observed in the H&E stained sections. Therefore, 
promoter restriction might not be necessary for limiting TRAIL expres-
sion in non-target tissues such as the liver (at least in mice). However, 
restricting transgene expression of TRAIL from liver could still be a con-
cern due to cell-mediated immunity against AAV capsid or the trans-
gene,35,48 especially in patients with underlying liver pathologies.49
In conclusion, systemically-delivered AAV9 encoding a therapeu-
tic protein is a promising approach to GBM therapy. Future experi-
ments using higher vector doses, different transgene expression 
cassettes, combined with TRAIL-sensitizing compounds should lead 
to a more pronounced survival benefit.
MATERIALS AND METHODS
Cloning
The pAAV-NSE-Fluc vector was constructed by digesting pAAV-NSE-GFP50 
and pAAV-CBA-Fluc51 with NheI and SacI (New England Biolabs, Ipswich, 
MA), replacing GFP with Fluc. The pAAV-CBA-sTRAIL vector has been previ-
ously described.52,53 From this vector, sTRAIL was amplified by polymerase 
chain reaction (PCR) using the following primers: AgeI forward 5′-GACAC-
CGGTGACGCCGCCACCATGACAG-3′ and SpeI reverse 5′-GGACTAGTTTAGC-
CAACTAAAAAGGCCCCGAA-3′. After digesting sTRAIL with AgeI and SpeI, 
respective inserts were ligated into a similarly digested pAAV-NSE-GFP, gen-
erating pAAV-NSE-sTRAIL.
Cell culture and viral vector production
293T cells, for AAV production, obtained from American Type Culture 
Collection (ATCC, Manassas, VA) were cultured in high-glucose Dulbecco’s 
modified eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented 
with 10% fetal bovine serum (FBS; Sigma, St. Louis, MO), 100 U of penicil-
lin/0.1 mg/ml streptomycin complex (Pen/Strep; Invitrogen, Carlsbad, CA). 
Primary stem-like GBM8 glioblastoma cells24 were cultured as neurospheres 
in serum-free NeuroCult NS-A Basal Medium with Proliferation Supplement 
(StemCell Technologies, Vancouver, BC), supplemented with 20 ng/ml 
recombinant epidermal growth factor (EGF; R&D Systems, Minneapolis, MN), 
10 ng/ml basic fibroblast growth factor (bFGF; Peprotech, Rocky Hill, NJ), 
Figure 4 Systemic delivery of AAV9-sTRAIL slows invasive GBM tumor growth in the brain. Mice were intracranially injected with patient-derived 
GBM stem-like neurospheres expressing Fluc (GBM-Fluc). Twenty-eight days later, mice were randomized into three groups, which were i.v. injected 
with 2 × 1013 g.c./kg of either AAV9-GFP control, AAV9-NSE-sTRAIL or AAV9-CBA-sTRAIL. (a) Weekly bioluminescence imaging was used to monitor 
tumor response. Arrow indicates the start of the treatment. (b) A representative bioluminescence image of a single mouse from each group is 
shown at different time points. (c) Kaplan-Meier survival curves for the three different treatment groups. (d) H&E and Ki-67 staining of brain sections. 
A representative section of a mouse from each group is shown at six weeks post-tumor inoculation.
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and 2 µg/ml heparin (Sigma). All cells were cultured at 37 °C under 5% CO2 
humidified atmosphere.
AAV vectors were produced as previously described.54 Briefly, triple trans-
fection of 293T cells using calcium phosphate precipitation was used with 
AAV2 ITR-containing single-stranded transgene plasmid, mini-adenovirus 
helper plasmid pFD6, and pH22 (AAV2 capsid; for in vitro use) or pAR9 (AAV9 
capsid; for in vivo use) rep/cap plasmid. Three days later, the cells were har-
vested, lysed by freeze/thaw, and AAV was purified using iodixanol density 
gradient ultracentrifugation, resulting in typical yields of 1013 genome copies 
per ml (g.c./ml).
Cell viability assay
For production of sTRAIL protein, 4 × 105 293T cells per well were plated 
in a 12-well plate. The next day, cells were transduced with 1 × 104 g.c./cell 
AAV2-NSE-Fluc (control), AAV2-NSE-sTRAIL, or AAV2-CBA-sTRAIL. We have 
previously shown that the NSE promoter is active in 293T cells.50 The day 
after 293T cell transduction, 5 × 103 GBM8 cells were plated in each well of a 
96-well plate. Two days later, conditioned medium from 293T producer cells 
was harvested and added to the GBM8 cells for all conditions in triplicate. 
Twenty-four hours after treatment, quantification of cell viability and ATP 
detection in metabolically active cells was performed using the commer-
cially available CellTiter-Glo assay as per manufacturer’s protocol (Promega, 
Madison, WI). Readout of relative light units (RLUs) was performed using a 
luminometer (Dynex Technologies, Chantilly, VA) and control samples were 
used to assess background signal in the medium and cell viability in each 
treatment group. After subtraction of background, the mean RLU per group 
was plotted as a percentage, with the control group set at 100%.
GBM animal models and bioluminescence imaging
All animal experiments were approved by the Massachusetts General 
Hospital (MGH) subcommittee on Research Animal Care and performed 
according to their guidelines and regulations. Female athymic nude mice of 
6–8 weeks old, weighing 20–25 g, were obtained from MGH research  animal 
services, and housed at their animal facility. For tail vein injections, each 
mouse was placed in a restrainer (Braintree Scientific, Braintree, MA); the tail 
was warmed up in a beaker with water at 40 °C and swabbed with alcohol. 
Mice were injected i.v. with a 200 µl mixture of PBS containing 1.5 × 1012 g.c./kg 
of either AAV9-CBA-Fluc or AAV9-NSE-Fluc vector, or 5 × 1013 g.c./kg of AAV9-
CBA-GFP or AAV9-NSE-GFP vector, or 2 × 1013 g.c./kg of AAV9-CBA-sTRAIL or 
AAV9-NSE-sTRAIL vector.
To generate GBM models, mice were anesthetized with a mixture of 
100 mg/kg ketamine and 5 mg/kg xylazine in 0.9% sterile saline. Mice were 
placed in a stereotaxic frame and intracranially injected with 2 × 104 GBM8-
Fluc cells using a Micro 4 Microsyringe Pump Controller (World Precision 
Instruments, Sarasota, FL) attached to a Hamilton syringe with a 33-gauge 
needle (Hamilton, Reno, NV), at the following coordinates in mm from 
bregma: +0.5 antero-posterior, +2.0 medio-lateral, -2.5 dorso-ventral.
To assess the transduction efficiency of AAV9-Fluc vectors or GBM8-Fluc 
tumor growth, Fluc expression in mice was imaged noninvasively using a 
Xenogen IVIS Spectrum charge-coupled device (CCD) camera (Caliper Life 
Sciences, Hopkinton, MA), equipped with an XGI-8 gas anesthesia system. 
Mice were anesthetized with 2.5% isoflurane in oxygen and the Fluc signal 
was acquired 10 minutes after i.p. injection of 200 mg/kg D-luciferin (Gold 
Biotechnology, St. Louis, MO) using the auto-exposure function. For AAV9-
Fluc vectors, the dorsal and ventral sides of mice were imaged for Fluc 
expression. The Living Image software package was used to draw a region 
of interest (ROI) around the abdomen or the head of mice and to quantify 
intensity of luminescent signal.
Tissue homogenates
Twenty days after AAV9-Fluc vector injections (n = 4 per group), mice were 
anesthetized and sacrificed by i.p. injection with an overdose mixture of ket-
amine (300 mg/kg) and xylazine (15 mg/kg) in sterile 0.9% saline. Liver and 
brain were harvested, snap frozen on liquid nitrogen and stored at −80 °C. For 
ex vivo assays, 50 mg of each tissue was lysed in a 96-deepwell plate (Nunc/
Thermo Fisher Scientific, Waltham, MA) by adding a stainless steel bead 
(Qiagen, Valencia, CA) and 500 µl of Mammalian Protein Extraction Reagent 
(M-PER; Pierce Biotechnology, Rockford, IL) and homogenized using the 
TissueLyser II (Qiagen) at 7.0 Hz for four times 3 minutes. The adapter hold-
ing the plate was inversed each time to ensure proper lysing. Next, the plate 
was centrifuged for 5 minutes at 1,200 rpm. The Bradford assay (Bio-Rad 
Labs, Hercules, CA) was performed according to manufacturer’s protocol to 
quantify protein amounts in each sample. Each homogenized sample was 
diluted 1 to 50 in order to be in the linear range of the microplate standard 
assay. For the Fluc assay, 20 µl of each homogenized tissue was transferred 
to a 96-well white bottom place. The luminometer (Dynex Technologies, 
Chantilly, VA) was programmed to add 100 µl of Bright-Glo Fluc substrate 
reagent (Promega, Madison, WI) to each well and analyze the signal during 
a ten-second integrated reading. Individual values of milligram protein and 
Fluc RLU for each tissue sample were obtained. After subtraction of back-
ground, the RLU/mg protein was calculated for matched samples.
Fluorescence, histology, and immunohistochemistry
Fifteen days post-i.v. injection of 5 × 1013 g.c./kg AAV9-CBA-GFP or AAV9-NSE-
GFP (n = 3 per group), mice were anesthetized and transcardially  perfused 
with PBS for 3 minutes to flush out the blood, followed by 4% paraformal-
dehyde (PFA; Affymetrix/USB Products, Santa Clara, CA) for 7 minutes to fix 
tissues. The brain and liver from each mouse were harvested, postfixed for 
24–48 hours in 4% PFA at 4 °C and then transferred to 30% sucrose in PBS for 
48–72 hours at 4 °C for cryoprotection. Tissues were embedded in Neg-50 fro-
zen section medium (Fisher Scientific, Pittsburgh, PA) using a dry ice/2-ethyl-
butanol bath and mounted in a Microm HM550 cryostat (Thermo Scientific, 
Kalamazoo, MI). Throughout the entire brain or liver, one-in-five 40 µm-thick 
coronal sections were collected in two (liver) or three (brain) consecutive 
series, transferred to a 24-well plate containing PBS kept on ice, and stored at 
4 °C. Immunofluorescence was performed on free-floating sections. The sec-
tions were permeabilized using 0.5% Triton X-100 in PBS and nonspecific bind-
ing was blocked with 5% normal goat serum (NGS) in PBS. Primary antibody 
specific for GFP (rabbit anti-GFP, ABfinity, 1:400; Life Technologies, Carlsbad, 
CA) was diluted in 1.5% NGS in PBS and incubated for 60 hours at 4 °C in stir-
ring condition. Next, 1:1,000 diluted secondary antibody (goat anti-rabbit 
Alexa Fluor 488, Cell Signaling, Danvers, MA) was incubated for 1 hour at room 
temperature in stirring condition. Nucleic staining was performed with DAPI, 
and, after final washes in PBS, sections were carefully mounted onto slides 
using a brush and dried overnight. Finally, fluorescence mounting medium 
(Dako North America, Carpinteria, CA) was applied and sections were covered 
with a coverslip. Once the mounting medium dried, slides were viewed under 
a Zeiss AxioObserver Z1 fluorescence microscope (Carl Zeiss Microscopy, 
Thornwood, NY) with an automated stage for capturing images using the Zen 
software package (Carl Zeiss Microscopy, Thornwood, NY). Cell type was deter-
mined based on morphology. The number of GFP+ cells for each cell type was 
counted per section and then averaged over the total area in mm2.
Statistics
Statistical analysis was performed using GraphPad Prism (v6.01; LaJolla, 
CA). A P value ≤ 0.05 was considered statistically significant. To compare 
promoter differences between tissues or between days, a two-way analysis 
of variance was used followed by a Sidak Multiple Comparison test to com-
pare individual groups. Otherwise, comparisons between two samples were 
analyzed using an unpaired two-tailed t-test. For analysis between multiple 
groups, a one-way analysis of variance was performed, again followed by a 
Sidak Multiple Comparison Test. Survival was analyzed using Kaplan-Meier 
curves and log-rank (Mantel-Cox) tests to compare all or individual groups.
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